TP53 and B-cell chronic lymphocytic leukemia: Regarding the entire CLL cohort, we observed that patients harboring a biallelic TP53 inactivation showed a significantly shorter overall survival than those with monoallelic TP53 alteration (median 19 vs 60 months, p = 0.016) (Figure S2A).